Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice 0.0020 smacks!
Holding as well. No reason DRNK can't go to a penny plus again once current.
Yeah I'm loading huge. These are bottom prices here. I've cashed on 6 DRNK runs this year, some bigger than others. This next one is going to be huge.
GO DRNK!!!
$BPSR So lucky to get some 0.181s today. This going to be a beast very soon!
Nasdaq uplist is already in process per PR. Most likely an RS announcement soon - reason for the halt. Than they get moved.
Just found this. This is probably the extremely important deadline (June 30th) Landrew was referring to and says he is confident UNSS will meet:
ALERT: The upcoming implementation of amended SEC Rule 15c2-11 will require that all companies quoted on our markets must disclose current information on a continuous basis, effective September 28, 2021.
Pink companies will need to update their disclosure to ensure they comply with the new requirements.
Alternative Reporting Companies and Bank Reporting Companies: OTC Markets has updated the Disclosure Guidelines for Alternative Reporting Companies to include all the information required under amended Rule 15c2-11. Companies must follow the Guidelines to be designated “Current Information” or “Limited Information” and remain publicly quoted.
International Reporting Companies – Companies that are current in their periodic disclosure and are listed on a Qualified Foreign Exchange that requires disclosure in English will remain in compliance and may continue to be publicly quoted. Other international companies seeking to ensure their ongoing compliance may publish their disclosure directly to OTC Markets for review.
Impacted Pink companies should provide the required disclosure to OTC Markets by June 30th. This will ensure that our Issuer Compliance Team has sufficient time to review and update market status for companies prior to the rule’s compliance date on September 28th. Securities that do not meet the Rule’s disclosure standard will have their public quotes removed from Pink as of the September deadline.
Contact issuers@otcmarkets.com for more information.
https://www.otcmarkets.com/corporate-services/information-for-pink-companies
Wow, what a close! Someone knows something.
DRNK
Another huge market opportunity. Entrex is relentless!
100% agree! The sky's the limit once CE is removed. PPS has been holding up remarkably despite the delays which proves shares are mostly held by Longs.
My hope is that CE will be removed within a week after Fins and Attorney Letter is submitted, like it was the case for CU*V (about 3-4 days) and another stock recently. Combine that with a juicy revenue deal and we are off to the races.
UNSS LONG & STRONG
CE removal is not in his control, so I think he means deadline for filings. TD is only one very specific platform of many and he didn't refer to it in his email. My 2 cents Lol
$BPSR HUGE NEWS Organicell Signs An Exclusive Distribution Agreement With Apex Services In Pakistan
https://organicell.com/2021/05/19/organicell-signs-an-exclusive-distribution-agreement-with-apex-services-in-pakistan/
PRESS RELEASE
Miami, FL (May 19, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has signed an exclusive distribution agreement with Apex Services Pakistan to import and distribute Zofin™ to hospitals and clinics in the country.
Under the agreement finalized this month, Apex Services will exclusively market, promote and distribute Zofin™ in the country of Pakistan in connection with treatments for COVID-19 patients, subject to the approval of all necessary licenses for the use of Zofin™ by the Drug Regulatory Authority of Pakistan. Earlier this month, the Drug Regulatory Authority of Pakistan approved the use of Zofin™ for a single patient on compassionate grounds.
If the use of Zofin™ is ultimately approved for use by a larger population, Apex Services will have exclusivity, subject to achievement of minimum sales levels. The initial term of the agreement is for one year and may be renewed based on certain conditions.
“With the execution of this distribution agreement, we are now better prepared to be able to provide additional help and further access to those in Pakistan who are suffering from complications from the COVID-19 virus pandemic to Zofin™. This will also support our plans to launch a broader clinical trial for Zofin™ in the country,” said Albert Mitrani, CEO of Organicell.
About Zofin™:
Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin™ is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to SARS related to COVID-19 infection vs placebo.
ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.
FORWARD-LOOKING STATEMENTS
Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will,” “believes,” “expects,” “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.
Media Contact:
Jeanene Timberlake
RooneyPartners
646-770-8858
$BPSR Organicell Signs An Exclusive Distribution Agreement With Apex Services In Pakistan
https://organicell.com/2021/05/19/organicell-signs-an-exclusive-distribution-agreement-with-apex-services-in-pakistan/
PRESS RELEASE
Miami, FL (May 19, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has signed an exclusive distribution agreement with Apex Services Pakistan to import and distribute Zofin™ to hospitals and clinics in the country.
Under the agreement finalized this month, Apex Services will exclusively market, promote and distribute Zofin™ in the country of Pakistan in connection with treatments for COVID-19 patients, subject to the approval of all necessary licenses for the use of Zofin™ by the Drug Regulatory Authority of Pakistan. Earlier this month, the Drug Regulatory Authority of Pakistan approved the use of Zofin™ for a single patient on compassionate grounds.
If the use of Zofin™ is ultimately approved for use by a larger population, Apex Services will have exclusivity, subject to achievement of minimum sales levels. The initial term of the agreement is for one year and may be renewed based on certain conditions.
“With the execution of this distribution agreement, we are now better prepared to be able to provide additional help and further access to those in Pakistan who are suffering from complications from the COVID-19 virus pandemic to Zofin™. This will also support our plans to launch a broader clinical trial for Zofin™ in the country,” said Albert Mitrani, CEO of Organicell.
About Zofin™:
Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin™ is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to SARS related to COVID-19 infection vs placebo.
ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.
FORWARD-LOOKING STATEMENTS
Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will,” “believes,” “expects,” “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.
Media Contact:
Jeanene Timberlake
RooneyPartners
646-770-8858
That's a good reason and makes sense!
Yes Sir. Am I am pumped! Lol
I believe he's referring to the deadline for Q1 filing this year. I could be wrong, but I believe this is 60 days after the end of the quarter, so end of May (soon!). Someone else can confirm perhaps, here.
Update from Paul Landrew Re: Fins!!!
"Paul Landrew <paul.landrew@universalsolartechnology.com>
Tue 2021-05-18 1:20 PM
***,
As you might imagine, there is a surge of activity and ALL CPA's are literally swamped. There are several parts to us getting the
financials done and we are close on ALL FRONTS. I am confident that we will beat the deadlines. I am not happy about the
delay, but I see the benefit for the long term.
Thank You for always being positive!
pdl"
The pandemic has been challenging for many and affected the pace of business.
We have all stayed very patient, and soon we will all be rewarded! AIMHO
UNSS LONG & STRONG
GREEN Up 22.6%!! Nice finish and could gap up tomorrow. Patient investors will be rewarded here - AIMHO.
BPSR = LIFe CHANGER
"Organicell is pleased to announce that we will be presenting our research titled “Administration of Amniotic Fluid derived Extracellular Vesicles in COVID-19 Long Hauler Patients” as a poster presentation at the #ISEV2021 Annual Meeting on May 18-21. ?Register to learn more!"
Organicell is pleased to announce that we will be presenting our research titled “Administration of Amniotic Fluid derived Extracellular Vesicles in COVID-19 Long Hauler Patients” as a poster presentation at the #ISEV2021 Annual Meeting on May 18-21. Register to learn more! pic.twitter.com/GhcbPR4BNs
— Organicell (@organicellTM) May 17, 2021
That's excellent news. That confirms they sent them to OTC as tweeted and need to tweak them. Thanks for sharing!
GO DRNK!
*under a dime
Something tells me this will never go a dime again. If it does, I'm adding!
Excellent! Got a really good feeling about this one. GLTA!
Not all RS are bad because that will attract institutional investors. Once Covid treatment is approved, this will go to multiple dollars IMO, so it won't be big RS.
Organicell Begins Up-Listing Process On NASDAQ Exchange
PRESS RELEASE
Miami, FL (May 4, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it is currently exploring options to up-list its common stock to the NASDAQ Capital Market tier of the NASDAQ Stock Market, LLC.
To qualify and be approved for such up-listing, the Company would be required to meet all financial, share price and corporate governance listing requirements of NASDAQ, which for the NASDAQ Capital Market includes a minimum of $5 million in shareholder equity and a minimum trading price of $4.00 per share. In order to meet these criteria, the Company would likely need to raise additional capital in one or more private or public offerings, as well as implement a reverse stock split or other recapitalization to meet the minimum trading price requirement. There can be no assurance that the Company will be able to do so or, that NASDAQ will list our shares of common stock for trading even if we do meet the minimum listing requirements.
“Up-listing on the NASDAQ Exchange is a strategic priority for Organicell. We want to ensure liquidity for our shareholders, access to the capital markets to fund our clinical trials and a heightened visibility for our company,” said Albert Mitrani, CEO of Organicell.
ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.
FORWARD-LOOKING STATEMENTS
Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will,” “believes,” “expects,” “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.
Media Contact:
Jeffrey Freedman
RooneyPartners
646-432-0191
jfreedman@rooneyco.com
Today Organicell announced that it is currently exploring options to up-list its common stock to the NASDAQ Capital Market tier of the NASDAQ Stock Market, LLC. https://t.co/Gx7626RrEl#BPSR #Organicell pic.twitter.com/xUBMVEPqxZ
— Organicell (@organicellTM) May 4, 2021
Great finish to the day here!
Is your CAPS button broken or something? Lol
Wow, that's a small float. No wonder it moves so fast!
I noticed that today, as well. Probably not huge but that's revenue for Entrex and one of many transactions to come.
Agreed. Quiet before the storm here.
BPSR CODID-19 treatment stock is going to be a Monster soon!
That's great! Those guys are going to be busy auditing carbon credit suppliers for Entrex in the coming months and years. :)
TBPMF PPS climbing back up. It was oversold on capital raise news, but the flock is coming back realizing how big a deal trial results will be.
Well said. A lot of misinformation is being spread by non share owners who haven't done their DD. You have to question their motives!
Same!! Hopefully the investment community pays attention if trials are successful.
You don't know anything about the situation Lol. See, we've done our DD here and didn't sell early.
I recall CE was removed on April 28th for CUBV (they announced it on Twitter), so it seems not all CE removals are on that OTC List.
$SHGFF GOING to NASDAQ announced just now! BOOOMMMM!!!!
https://www.globenewswire.com/news-release/2021/05/13/2229365/0/en/Skylight-Health-Obtains-Conditional-Approval-to-List-on-NASDAQ-Under-the-Symbol-SLHG.html
Skylight Health Obtains Conditional Approval to List on NASDAQ Under the Symbol “SLHG”
May 13, 2021 13:21 ET | Source: Skylight Health Group Inc.
...
TORONTO, May 13, 2021 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, today announced that the Company has received conditional approval from The Nasdaq Stock Market LLC ( “Nasdaq”) to list its issued and outstanding common shares on Nasdaq. Final approval of the listing is subject to the Company fulfilling any remaining conditions as required by Nasdaq. The Company expects to satisfy all of the requirements and will issue a statement once a trading date has been confirmed by Nasdaq. The Company’s common stock will continue to trade in Canada on the TSX Venture Exchange under its current symbol SHG; and until the NASDAQ listing, in the U.S. on the OTCQX under its current symbol, SHGFF.
“The anticipated listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly-traded company,” said Prad Sekar, CEO and Co-Founder of Skylight Health. “We believe this anticipated listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value. I would like to thank our employees, management, directors and our many collaborators for their hard work in obtaining conditional approval for Skylight Health to list on Nasdaq, an important step that will help facilitate our mission to provide primary services to Americans across the country.”
The Company also announces a change in auditor from Grant Thornton LLP (“Former Auditor”) to PricewaterhouseCoopers LLP (“Successor Auditor”) effective May 4, 2021. In accordance with NI 51-102, the notice of change of auditor, together with the required letters from the Former Auditor and the Successor Auditor, have been reviewed by the board of directors of the Company and filed on SEDAR.
About Skylight Health Group
Skylight Health Group (TSXV:SHG; OTCQX:SHGFF) is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state health network that comprises of physical multi-disciplinary medical clinics providing a range of services from primary care, sub-specialty, allied health and laboratory/diagnostic testing. The Company owns and operates a proprietary electronic health record system that supports the delivery of care to patients via telemedicine and other remote monitoring system integrations.
The Company primarily operates a traditional insurable fee-for-service model contracting with Medicare, Medicaid and other Commercial Payors. The Company also offers a disruptive subscription-based telemedicine service for the un/under-insured population who have limited access to urgent care due to cost.
For more information, please visit www.skylighthealthgroup.com or contact:
Investor Relations – USA:
John Evans
john.evans@skylighthealthgroup.com
Investor Relations - Canada:
Jackie Kelly
investors@skylighthealthgroup.com
416-301-2949
Currency Usage, Cautionary and Forward-Looking Statements
All currency contained in this Press Release represent Canadian Dollars unless otherwise stated.
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Skylight Health's filings with Canadian and United States securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.
Forward-looking statements may include, without limitation, statements regarding the Company’s anticipated uplist to NASDAQ.
Although Skylight Health has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: the ability of Skylight Health to execute on its business strategy, continued revenue growth in accordance with management’s expectations, operating expenses continuing in accordance with management expectations, dependence on obtaining regulatory approvals; Skylight Health being able to find, complete and effectively integrate target acquisitions; change in laws relating to health care regulation; reliance on management; requirements for additional financing; competition; hindering market growth or other factors that may not currently be known by the Company.
There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Skylight Health disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Skylight Health does not assume any liability for disclosure relating to any other company mentioned herein.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
WOW GOING to NASDAQ is HUGE NEWS!
https://www.globenewswire.com/news-release/2021/05/13/2229365/0/en/Skylight-Health-Obtains-Conditional-Approval-to-List-on-NASDAQ-Under-the-Symbol-SLHG.html
Skylight Health Obtains Conditional Approval to List on NASDAQ Under the Symbol “SLHG”
May 13, 2021 13:21 ET | Source: Skylight Health Group Inc.
TORONTO, May 13, 2021 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, today announced that the Company has received conditional approval from The Nasdaq Stock Market LLC ( “Nasdaq”) to list its issued and outstanding common shares on Nasdaq. Final approval of the listing is subject to the Company fulfilling any remaining conditions as required by Nasdaq. The Company expects to satisfy all of the requirements and will issue a statement once a trading date has been confirmed by Nasdaq. The Company’s common stock will continue to trade in Canada on the TSX Venture Exchange under its current symbol SHG; and until the NASDAQ listing, in the U.S. on the OTCQX under its current symbol, SHGFF.
“The anticipated listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly-traded company,” said Prad Sekar, CEO and Co-Founder of Skylight Health. “We believe this anticipated listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value. I would like to thank our employees, management, directors and our many collaborators for their hard work in obtaining conditional approval for Skylight Health to list on Nasdaq, an important step that will help facilitate our mission to provide primary services to Americans across the country.”
The Company also announces a change in auditor from Grant Thornton LLP (“Former Auditor”) to PricewaterhouseCoopers LLP (“Successor Auditor”) effective May 4, 2021. In accordance with NI 51-102, the notice of change of auditor, together with the required letters from the Former Auditor and the Successor Auditor, have been reviewed by the board of directors of the Company and filed on SEDAR.
About Skylight Health Group
Skylight Health Group (TSXV:SHG; OTCQX:SHGFF) is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state health network that comprises of physical multi-disciplinary medical clinics providing a range of services from primary care, sub-specialty, allied health and laboratory/diagnostic testing. The Company owns and operates a proprietary electronic health record system that supports the delivery of care to patients via telemedicine and other remote monitoring system integrations.
The Company primarily operates a traditional insurable fee-for-service model contracting with Medicare, Medicaid and other Commercial Payors. The Company also offers a disruptive subscription-based telemedicine service for the un/under-insured population who have limited access to urgent care due to cost.
For more information, please visit www.skylighthealthgroup.com or contact:
Investor Relations – USA:
John Evans
john.evans@skylighthealthgroup.com
Investor Relations - Canada:
Jackie Kelly
investors@skylighthealthgroup.com
416-301-2949
Currency Usage, Cautionary and Forward-Looking Statements
All currency contained in this Press Release represent Canadian Dollars unless otherwise stated.
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Skylight Health's filings with Canadian and United States securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.
Forward-looking statements may include, without limitation, statements regarding the Company’s anticipated uplist to NASDAQ.
Although Skylight Health has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: the ability of Skylight Health to execute on its business strategy, continued revenue growth in accordance with management’s expectations, operating expenses continuing in accordance with management expectations, dependence on obtaining regulatory approvals; Skylight Health being able to find, complete and effectively integrate target acquisitions; change in laws relating to health care regulation; reliance on management; requirements for additional financing; competition; hindering market growth or other factors that may not currently be known by the Company.
There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Skylight Health disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Skylight Health does not assume any liability for disclosure relating to any other company mentioned herein.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Wow. So many people want to buy but have to wait for CE removal. Should go parabolic after that!
0.0023s filled! $DRNK Let's GO!!!!!
Missed your post. Yeah, let's hope we get the same treatment once uploaded.